In vitro assay based on human cells to demonstrate increased migration capacity of therapeutic immune cells
2018
University of Antwerp, Wilrijk, Belgium
Multiple sclerosis (MS) is a chronic autoinflammatory disease of the central nervous system. Although tolerance-inducing dendritic cells (tolDCs) have been shown to be promising therapeutics to control the inflammation process, the clinical use of these cells depends largely on their capacity to migrate and reach target organs. In the present study, the researchers increased the migration capacity of dendritic cells by overexpressing one particular gene involved in migration and demonstrated it in an in vitro model of the blood-brain barrier (BBB). Dendritic cells were prepared from blood obtained from healthy donors, the blood-brain barrier model was constructed by co-culturing human cells in different layers. The approach used herein has important implications for the treatment of MS. Using this approach, tolDCs actively shuttle across the BBB, allowing in situ down-modulation of autoimmune responses in the CNS.
Shuttling tolerogenic dendritic cells across the blood–brain barrier in vitro via the introduction of de novo C–C chemokine receptor 5 expression using messenger RNA electroporation
Nathalie Cools
Added on: 09-20-2021
[1] https://www.frontiersin.org/articles/10.3389/fimmu.2017.01964/full[2] https://data.jrc.ec.europa.eu/dataset/c1c15110-2338-422e-a228-d3f8e19262c3
